Managing Discovery in the Life Sciences

Addresses in roughly equal measure the science and management behind several recent marketable biomedical innovations.

Key to biomedical innovation is scientific discovery and its translation into marketable products. This book addresses the link between life sciences discoveries and their dependence on the investor-driven market system through in-depth considerations of the challenges that both scientists and managers must face in the pharmaceutical and medical device industries.In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.